Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Glaucoma: Overview01:25

Glaucoma: Overview

1.5K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.5K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

71
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
71
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

880
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
880
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Off-label prescribing in ophthalmology: a retrospective analysis.

Frontiers in pharmacology·2026
Same author

Chemophysical Characterization of Carotenoproteins From Crustacean Shell Waste for Pharmaceutical Applications.

International journal of food science·2026
Same author

Effects of New P2X7R Antagonists on Retinal Inflammatory Degenerative Conditions.

Inflammation·2026
Same author

Activity dependent neuroprotective protein mediates the protective effects against VEGF-induced corneal barrier disruption in diabetes.

Peptides·2026
Same author

Selective phosphoinositide 3-kinase inhibitors and implication in diabetic retinopathy as pharmacological tools.

Frontiers in pharmacology·2026
Same author

Safety profile of lutein-based blue dyes and surgical lights.

Frontiers in pharmacology·2025

Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K

Novel Therapeutics in Glaucoma Management.

Claudio Bucolo1,2, Chiara Bianca Maria Platania1, Filippo Drago1,2

  • 1Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, Italy.

Current Neuropharmacology
|September 20, 2017
PubMed
Summary

This review explores novel experimental drugs for glaucoma management, focusing on neuroprotection beyond lowering intraocular pressure (IOP). It covers diverse therapeutic targets and existing drug benefits.

Keywords:
GlaucomaRho kinase inhibitorsanti-glaucoma drugsdopamine ligandshistone deacetylase inhibitorsintraocular pressurenitric oxidepurinergic ligandsretinal ganglion cells.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.9K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Related Experiment Videos

Last Updated: Feb 22, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.9K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is a progressive optic neuropathy causing retinal ganglion cell death and visual field loss.
  • Elevated intraocular pressure (IOP) is a primary risk factor, but epigenetic factors also play a role.
  • Understanding these mechanisms is crucial for developing effective glaucoma treatments.

Purpose of the Study:

  • To provide an overview of promising experimental drugs for glaucoma management.
  • To explore novel therapeutic targets beyond IOP reduction.
  • To review potential neuroprotective benefits of existing anti-glaucoma medications.

Main Methods:

  • Literature review of experimental drugs for glaucoma.
  • Focus on diverse pharmacological classes and molecular targets.
  • Inclusion of recent findings on neuroprotective agents.

Main Results:

  • Experimental drugs investigated include purinergic ligands, KATP channel activators, gases (NO, CO, H2S), and PI3K/Akt activators.
  • Other drug classes include steroidal compounds, neurotrophic factors, citicoline, HDAC inhibitors, cannabinoids, and receptor ligands.
  • Rho kinase inhibitors and small interfering RNA represent novel therapeutic strategies.

Conclusions:

  • Emerging experimental drugs offer new avenues for glaucoma treatment by targeting neuroprotection.
  • Existing anti-glaucoma drugs may possess neuroprotective properties warranting further investigation.
  • A multi-faceted approach combining IOP management and neuroprotection is essential for glaucoma therapy.